{"url_path":"/sec/armp/8-k/2026-07-20/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/921114/0001104659-26-084860-index.html","accession_number":"0001104659-26-084860","cik":"0000921114","ticker":"ARMP","issuer_name":"Armata Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/921114/0001104659-26-084860-index.html","primary_entity_key":"0000921114","primary_entity_name":"Armata Pharmaceuticals, Inc."},"word_count":294,"has_tables":true,"body_markdown":"false\n0000921114\n\n0000921114\n\n2026-07-17\n2026-07-17\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND\nEXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n** **\n\n**Pursuant to Section 13 OR 15(d) of\nThe Securities Exchange Act of 1934**\n\n** **\n\nDate of Report (Date of earliest event reported):\nJuly 17, 2026\n\n \n\n**ARMATA PHARMACEUTICALS, INC.**\n\n(Exact name of registrant as specified in\nits charter)\n\n \n\n**Washington**\n \n**001-37544**\n \n**91-1549568**\n\n(State or other jurisdiction\n\nof incorporation)\n \n(Commission File Number)\n \n(IRS Employer\n\nIdentification No.)\n\n \n\n**5005 McConnell Avenue,**\n**** **Los Angeles****, California**\n \n**** **90066**\n\n(Address of principal executive offices)\n \n(Zip Code)\n\n** **\n\n**(310) 655-2928**\n\n(Registrant’s telephone number, including area code)\n\n \n\n(Former name or former address, if changed since last report)\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule\n12b-2 of the Securities Exchange Act of 1934.\n\n \n\nEmerging Growth Company ¨\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨\n\n \n\nSecurities registered pursuant to Section 12(b) of\nthe Act:\n\n \n\n**Title\nof each class**\n** **\n**Trading\nSymbol(s)**\n** **\n**Name\nof each exchange on which registered**\n\nCommon\nStock\n \nARMP\n \nNYSE\nAmerican"}